Stocks and Investing Stocks and Investing
Wed, August 10, 2022
Tue, August 9, 2022

Brian Abrahams Maintained (SRPT) at Buy with Increased Target to $182 on, Aug 9th, 2022


Published on 2024-10-27 22:33:21 - WOPRAI, Brian Abrahams
  Print publication without navigation


Brian Abrahams of RBC Capital, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $160 to $182 on, Aug 9th, 2022.

Brian has made no other calls on SRPT in the last 4 months.



There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 2 agree with Brian's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Judah Frommer of "Credit Suisse" Maintained at Hold with Increased Target to $93 on, Wednesday, August 3rd, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $100 on, Wednesday, August 3rd, 2022


These are the ratings of the 3 analyists that currently disagree with Brian


  • Gil Blum of "Needham" Maintained at Strong Buy with Increased Target to $162 on, Friday, July 29th, 2022
  • Kristen Kluska of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $128 on, Friday, June 24th, 2022
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $107 on, Tuesday, April 19th, 2022
Contributing Sources